Drug Development Pharma - March 1, 2016
Update on Genmab’s ofatumumab development
Genmab A/S has announced an update on development plans for ofatumumab in autoimmune indications focusing on relapsing multiple sclerosis following the transfer of the rights to ofatumumab in this disease area from GlaxoSmithKline (GSK) to Novartis at the end of 2015. Phase III studies are expected to be initiated by Novartis with the subcutaneous formulation […]
Drug Development Pharma - June 9, 2015
Janssen Submits BLA to FDA
Genmab A/S’s licensing partner Janssen Biotech, Inc. has initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for daratumumab for double refractory multiple myeloma. The submission is for using daratumumab to treat patients with multiple myeloma who have received at least three different lines of therapy […]
Collaboration - December 15, 2014
Genmab Earns Milestone Fee
Genmab A/S announced it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc., triggering a $3 million payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. “This milestone marks further progress in our DuoBody collaboration with Janssen. There are now 10 bispecific antibody programs […]
Clinical Trials - November 10, 2014
New Myeloma Drug Study
Genmab A/S (OMX: GEN) announced that the French Intergroup of Myeloma (IFM) in collaboration with Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Biotech, Inc. is planning an additional Phase III study of daratumumab in frontline multiple myeloma. The study will compare daratumumab in combination with bortezomib, thalidomide and dexamethasone (VTD) to bortezomib, […]
Financing - January 28, 2014
Genmab raises DKK 998 million in private placement
Genmab have announced that it has raised gross proceeds of DKK 998 million following pricing of its previously announced private placement. Genmab will isuue 4,600,000 new shares with a nominal value of DKK 1 each at a price of DKK 217 per share. Potential uses for the net proceeds from the transaction may include, among […]
Collaboration - December 6, 2013
Genmab announces expansion with Janssen Biotech
Genmab have announced an expansion of its collaboration with Janssen Biotech to create and develop bispecific antibodies using the DuoBody technology platform. The original agreement entitled Janssen to work on up to ten DuoBody programs. Under the terms of the amendment, Janssen is entitled to work on up to ten additional programs. Genmab will receive […]
